News
Positive Results From LigoCyte’s Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting
October 25, 2010 /
LigoCyte Pharmaceuticals, Inc. http://www.ligocyte.com/ , a private, clinical-stage biopharmaceuticals company developing innovative vaccine products, today announced positive results from a Phase I/II challenge study of its norovirus virus-like particle (VLP) vaccine candidate. Baylor College of Medicine’s Robert Atmar, M.D., the study’s principal investigator, shared data from the trial via an oral presentation at the Infectious Diseases Society of America (IDSA) 2010 Annual Meeting on October 23 in Vancouver, British Columbia.
MATR Supporters (view all)
Posted in: Biotech
Sorry, we couldn't find any posts. Please try a different search.